Plus Therapeutics

About Plus Therapeutics

Plus Therapeutics is a biotech company focused on developing targeted radiotherapeutics for cancer treatment. Their mission is to deliver precise, high-dose radiation directly to tumors while minimizing damage to healthy tissue, aiming to improve outcomes for adults and children with rare and difficult-to-treat cancers.

Products & Services

REYOBIQ™ (rhenium Re186 obisbemeda):A Rhenium-186 radiolabeled nanoliposome therapy targeting brain and CNS cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM):A next-generation radioembolization therapy designed to treat solid organ cancers, including hepatocellular carcinoma and metastatic colorectal cancer, using Rhenium-188 radiolabeled nanoliposomes loaded into alginate microspheres.

Specialties

Targeted Radiotherapeutics Cancer Treatment Brain and CNS Cancers Solid Organ Cancers Rhenium Radioisotopes Nanoliposome Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 15000000 MR: - FA: 15 million FAN: 15000000	D: 2026-01-14 FD: 2026-01-14	1 investors
2	RT: Grant T: - FT: Grant	A: 1600000 MR: - FA: $1.6 million FAN: 1600000	D: 2025-07-23 FD: 2025-07-23	1 investors
3	RT: Grant Advance Payment T: - FT: Grant Advance Payment	A: 1600000 MR: - FA: $1.6M FAN: 1600000	D: 2025-07-23 FD: 2025-07-23	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 15000000 MR: - FA: approximately $15.0 million FAN: 15000000	D: 2025-03-04 FD: 2025-03-04	-
5	RT: Equity Financing T: - FT: Equity Financing	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-03-04 FD: 2025-03-04	-
6	RT: Private Placement T: - FT: Private Placement	A: 5700000 MR: - FA: $5.7 million FAN: 5700000	D: 2025-02-18 FD: 2025-02-18	3 investors
7	RT: Private Placement T: - FT: Private Placement	A: 18000000 MR: - FA: up to $18 million FAN: 18000000	D: 2024-05-06 FD: 2024-05-06	3 investors
8	RT: Grant T: - FT: Grant	A: 3000000 MR: - FA: $3 Million FAN: 3000000	D: 2024-04-22 FD: 2024-04-22	1 investors
9	RT: Grant T: - FT: Grant	A: 1900000 MR: - FA: approximately $1.9 million FAN: 1900000	D: 2023-09-11 FD: 2023-09-11	1 investors

Public Offering Latest

2026-01-14

$15.0M

1 investor (Pro only)

Grant 2025-07-23

$1.6M

Grant Advance Payment 2025-07-23

$1.6M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Marc Hedrick

President and CEO

A

Andrew Sims

Vice President and Chief Financial Officer

R

Russ Havranek

Vice President, Corporate Strategy and New Product Planning

M

Michael Rosol

Chief Development Officer

R

Russell Bradley

President and General Manager, CNSide Diagnostics

R

Richard Hawkins

Chairman

View 16 more team members with Pro

Unlock Full Team Directory

Recent News